June 2018

NCI Standard Funding Opportunity Announcements

Current and Recent Program Announcements  |  Current and Recent Requests for Applications
Current and Recent NCI and Trans-NIH Initiatives | Requests for Proposals  |  Standard Due Dates

Continuous All Ranks Non-federal Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma Research Foundation
Grant Opportunities

Projects supported by ACCRF fall into three broad categories:
1.    Specimens & Models - Researchers investigating ACC need certain building blocks as the foundation of their experiments. Biobanks (repositories for tumors, saliva, plasma and other specimens), cell lines (tumor cells grown in dishes) and animal models (tumors grown typically in mice). ACCRF is committed to increasing availability of, and access to, these crucial building blocks.
2.    Basic Research - To accelerate development of improved therapies, projects that reveal the mechanisms of action that are driving the genesis, development and progression of ACC
3.    Translational Research -  Before a novel therapy can reach the bedside, it must pass many tests of safety and efficacy. ACCRF is preparing an open and efficient infrastructure to conduct high-throughput screening of compounds in cell lines and animal models. In addition, ACCRF is exploring ways to support clinical trials for ACC patients, whether for novel compounds or drugs already approved for other indications.
Due Dates: Continuous - Researchers wishing to submit a proposal should email ACCRF's Executive Director w/a 1 paragraph description of research project. If determined  to be w/in  research priorities, a request for a full proposal will be issued.
Amount & Project Period: Not stated
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Links: Grant Opportunities
ACCRF Research Agenda


UPDATED
Rolling Clinical Faculty Non-federal Personalized/Precision Medicine

Gateway for Cancer Research
Single or Collaborative Grants Supporting Patient-centered Phase I and Phase II Clinical Trials

The moratorium on application submissions has been lifted.  At this time Letters of Intent can be accepted through Gateway's Grants Management System (GMS).  Personalized medicine/precision medicine applications are highly encouraged. For Gateway, personalized medicine/precision medicine means: Treatment precisely customized to the characteristics of each individual's tumor and host. Personalized medicine may include complementary therapies, immunotherapies, genomic therapies, and patient preferences. Personalized medicine may include N-of-1 studies, but is not limited to these types of studies.
Due Dates: Rolling requests for funding conducted in two stages: a Letter of Intent (LOI) and if invited, a full application. Applicants must via Gateway's Grant Management System  
Amount & Project Period: Funding is variable and duration is 1 to 3 years
Eligibility: All Ranks
Contact: Domarina Oshana, PhD, Director, Research and Grants
Tel: (847) 342-7443
Link: Apply for a Grant
Continuous All Ranks Non-federal Blood Cancers

The Ryan Gibson Foundation
Research that Saves - Grants

Research grant requests from around the country are welcomed at any time. The main focus is on blood related cancers. To be considered please submit a one to two page proposal with the following information.
   A description of the procedure and or drug planned for testing/developing and desired results;
   Background on researcher and facility to be used. Past projects success and or failures should
   be included;
   A budget of anticipated costs.
Due Dates: A one to two page proposal can be submitted any time.
Amount & Project Period: Not stated.  Budget and performance period requested should be reasonable in accordance with project proposed.
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: Research that Saves - Grants


NEW
Continuous All Ranks Non-federal Sarcoma

The Alan B. Slifka Foundation
Sarcoma Research Grants Initiative

The Foundation funds a wide range of sarcoma research topics (See What We Fund).  Grants may be used for development of models; conduct of experiments; development of sarcoma tissue registries; and similar activities related to research into the causes, origins, development, metastasis, molecular biology, diagnosis and treatment of sarcomas. Proposals that pursue studies with patients undergoing treatment or who are participating in an investigational study are considered and have been supported.
Due Dates:  A researcher may submit a letter of intent at any time, but grant applications are by invitation only. The peer-review process typically takes 2-4 months.)
Amount & Project Period: $50,000 - 1 year
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: Sarcoma Research Grants Initiative


To Be Announced See Program Announcement Federal Prostate Cancer

Congressionally  Directed Medical Research Programs
Upcoming Funding Opportunities - PCRP

Although funds have not been appropriated for FY18, CDMRP's Prostate Cancer Research Program (PCRP) is providing information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities. 

Department of Defense Prostate Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)


NEW
May 18 All Ranks Non-federal Gynecologic Cancers

Ovarian Cancer Research Fund Alliance
Woman to Woman Support Program

OCRFA's Woman to Woman is a peer-to-peer support program for women with gynecologic cancers.  The programs pairs gynecologic cancer patients with trained survivor volunteers who provide one-on-one emotional support and mentoring to women when they need it most.  A grant opportunity is available to institutions with a large volume of gynecologic cancer patients and a need to provide this type of support service to patients. Grants are provided to cover the cost of a part-time Program Coordinator's salary, program costs, and the patient fund. It is expected that each Woman to Woman program will become self-funding.
Due Dates: May 16 (OSR) Ι (May 18 (Sponsor)
Applications should be sent to womantowoman@ocrfa.org
Amount & Project Period: $60,000 - Up to 2 years
Eligibility: The most competitive applicants will be hospitals or cancer centers that are able to demonstrate the following: adequate gynecologic oncology patient volume, physician and hospital leadership support, the need for the program, the ability to run patient-focused initiatives, and the ability to fundraise to support programs.
Contact: Office of Sponsored Research (x6804)
Links: About Woman to Woman Ι  RFP Ι  ApplyNow
R01 NHGRI

May 21 (LOI) All Ranks Federal Genomic Medicine

Investigator-Initiated Genomic Medicine Research (Clinical Trial Optional)

This FOA supports research opportunities to advance understanding and implementation of the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use.
Due Dates: May 21 (Letter of Intent, Optional)
Applications Due:  June 18 (OSR) Ι June 20 (Sponsor)
Additional Due Dates:  Oct. 19 &  June 20 and Oct. 21, 2019
Amount & Project Period: Must be under $500,000/yr. (Direct Costs) - 4 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-735
Companion FOA: PAR-18-736  R21

May 21 All Faculty Ranks Non-federal Childhood Cancer

Alex's Lemonade Stand Foundation for Childhood Cancer
2018 Reach Grants

Reach Grants are designed to move hypothesis-driven research into the clinic. The grant is intended to fund developmental therapeutic studies in the late stage of preclinical testing. A successful application will identify an unmet clinical need relevant to the care of pediatric patients with cancer and describe how the work performed will allow for the translation to the clinic w/in two years of completion. A plan and timeline for clinical testing and trial implementation is expected. This grant does not fund clinical trial expenses.
Due Dates: May 17 (OSR) Ι May 21 (Sponsor)
Amount & Project Period: $250,000 - 2 years
Eligibility: Assistant, Associate or Professor level investigators w/track record of discovery, investigation and external funding;
Must have a demonstrated track record of pediatric cancer research w/experience in translational research.
Contact: Office of Sponsored Research (x6804)
Link: 2018 Reach Guidelines



NCI participates NIH

May 22 All Ranks Federal Data-People-Systems

National Science Foundation (NSF) and National Institutes of Health (NIH)
Smart and Connected Health (SCH) Connecting Data, People and Systems

The purpose of this interagency program, supported by NSF and NIH, is to develop next-generation multidisciplinary science that encourages existing and new research communities to focus on breakthrough ideas in a variety of areas of value to health, such as networking, pervasive computing, advanced analytics, sensor integration, privacy and security, modeling of socio-behavioral and cognitive processes and system and process modeling. Effective solutions must satisfy a multitude of constraints arising from clinical/medical needs, barriers to change, heterogeneity of data, semantic mismatch and limitations of current cyberphysical systems and an aging population. Such solutions demand multidisciplinary teams ready to address issues ranging from fundamental science and engineering to medical and public health practice.
Due Dates: May 18 (OSR) Ι May 22 (Sponsor)
Additional Due Date:  Dec. 11th
Amount & Project Period: $300,000/yr. (Total) - up to 4 years
Eligibility: All Ranks - Note:  An investigator may participate as PI co-PI, Project Director (PD), Senior Personnel or Consultant in no more than 2 proposals submitted in response to this solicitation.
Contact: Office of Sponsored Research (x6804)
Links: Smart and Connected Health Ι NSF  18-541  



NEW
May 24 (LOI) Postdocs/Junior Faculty Non-federal Urological

American Urological Association
Rising Stars in Urology Research Awards

This program encourages recipients to contribute to urology as both surgical specialists and scientists investigating causes, prevention, treatment and cures that will improve patients' lives.  This program provides supplemental salary support to physician-scientist career development award recipients.
Due Dates: May 24 (Pre-application)
Applications Due:  June 05 (OSR) Ι June 07 (Sponsor)
Applicants must submit all documents via e-mail to grantsmanager@AUAnet.org.
Amount & Project Period: Period of salary supplementation will be commensurate w/period of performance of existing career development award. Funding: $28,000 in year 1; $33,000 in year 02; $40,000 in year 03; $46,000 in year 04; and $52,000 in year 05.  
Note that funds are disbursed directly to the individual awardee; taxes are not withheld from award payments so it is the responsibility of the awardee to ensure that appropriate federal and local taxes are accounted for.  Funds cannot be used for fringe benefits. Awardees may be personally responsible for repayment of funds provided by the award in the event that they fail to meet the obligations of the award described in Program Announcement.
Eligibility: Applicant must, by July 1, 2018:
Be a board-certified or -eligible urologist, or participating in a training program to obtain board certification in urology;
Have successfully competed for a new externally-funded, peer-reviewed, career development award (i.e., K07/K08/K23 awards from the NIH, or career development-type grants from the VA, DoD, American Cancer Society or others);
Have at least 2 full years remaining on period of performance for career development award;
Be focused on a research project that aligns with one or more of the research priorities described in the AUA's National Urology Research Agenda (NURA), and be conducting research within the boundaries of the eight sections of the AUA;
50% protected time for research is required
Contact: Office of Sponsored Research (x6804)
Link: Overview 

NEW
May 25 (LOI) Junior Faculty Non-federal Lung

A Breath of Hope Lung Foundation
Research Fellowships

This award is focused on innovative lung cancer research projects specifically designed to reduce the lung cancer mortality rate.
Due Dates: May 25 (Letter of Inquiry/eligibility form)
Invited Applications:  Jul. 12 (OSR) Ι July 15 (Sponsor)
Amount & Project Period: $150,000 - 2 years
Eligibility: Must be w/in first 7 years of a U.S. faculty appointment and focused on lung cancer;
Receiving $250,000 or less in other grant support
Contact: Office of Sponsored Research (x6804)
Links: Announcing 2018 RFP | 2018 Eligibility & Letter of Inquiry

May 25 Postdocs/New Faculty Non-federal Career Development/Myelomas

Multiple Myeloma Research Foundation (MMRF)
2018 Research Fellow Awards

The goal of this initiative is to help support young investigators to begin their studies in the field of multiple myeloma while advancing the understanding of myeloma disease biology, treatment and drug resistance.
Due Dates: May 23 (OSR) Ι May 25 (Sponsor)
Amount & Project Period: $75,000 - 1 year
Eligibility: Must hold a Ph.D., M.D. or equiv. degree;
Must be at post-doctorate, clinical fellow;
OR
Assistant professor level beginning studies in multiple myeloma field under supervision of a research mentor or sponsor;
Mentor required for both Postdoc and faculty applicants
Contact: Office of Sponsored Research (x6804)
Links: MMRF Research Grants
Program Guidelines | proposalCENTRAL  
R01 NIH
May 30 (LOI) All Ranks Federal Imaging

Early Phase Clinical Trials in Imaging and Image-Guided Interventions

This FOA is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools.
Due Dates: May 30 (Letter of Intent, not required or binding)
Applications Due:  June 24 (OSR) Ι June 28 (Sponsor)
Additional 2018 Due Date:  Oct. 11
Amount & Project Period: $500,000 (Direct Costs) for total period.  No more than $250,000 (Direct Costs) may be requested in any single year. - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-011
R01 NCI

May 30 (LOI) All Ranks Federal Provocative Cancer Questions

Research Answers to National Cancer Institute's (NCI) Provocative Questions (Clinical Trial Optional)

The purpose of these RFAs is to support research projects designed to solve specific problems and paradoxes in cancer research as identified by the NCI Provocative Questions initiative.  These problems and paradoxes phrased as questions are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.
Due Dates: May 30 (Letter of Intent, not required or binding)
Applications Due: June 27 (OSR) Ι June 29 (Sponsor)
Additional 2018 Due Date: Oct. 30
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA-CA-18-019
Companion RFA: RFA-CA-18-020 (R21)
Additional Note: Four additional FOAs are planned for revision applications (formerly known as competing supplements) to add PQ-relevant research to specific eligible NIH and/or NCI-supported parent awards.  Watch for RFA-CA-18-020, RFA-CA-18-022, RFA-CA-18-023, and RFA-CA-18-024 for R01, U01, P01, and P50 awards, respectively.

NEW
May 30 (Pre-application) See Below Federal Ovarian

Congressionally Directed Medical Research Programs
Ovarian Cancer Research Program
FY2018 Funding Opportunities

Due Dates: May 30 (Pre-application)
Invited Applications Due:  Aug. 20 (OSR) Ι Aug. 22 (Sponsor)
Contact: Office of Sponsored Research (x6804)
Primary Links: FY18 Ovarian Cancer Research Program (OCRP)
Program Funding Opportunities Ι Application Instructions
 

Investigator-Initiated Research Award
W81XWH-18-OCRP-IIRA

This award is intended to support high-impact research having the potential to make an important contribution to ovarian cancer or patient/survivor care. Projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials.  Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project.
Amount & Project Period: $450,000 (Direct Costs) - 3years
Eligibility: Independent investigators at or above the level of Assistant Professor (or equiv.)
Link: W81XWH-18-OCRP-IIRA 
 

Pilot Award
W81XWH-18-OCRP-PA

This award supports exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. Inclusion of preliminary data is not required, but allowed.  The strength of the application should be based on sound scientific rationale and logical reasoning. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects. Clinical trials will not be supported by this award mechanism.
Amount & Project Period: $250,000(Direct Costs) - 2 years
Eligibility: Investigators at postdoctoral level and above (and equiv.); Investigators should have either dedicated or shared laboratory space.
Link: W81XWH-18-OCRP-PA

May 31 All Ranks Non-federal Ovarian

Louisa M. McGregor Ovarian Cancer Foundation
2018 T.E.A.L.® Medical Research and Awareness Program Beneficiary

This program offers funding in support of ovarian cancer research studies that are most aligned with that mission as determined by the T.E.A.L.® board of directors and scientific advisory board. The mission is to promote public awareness of and education about signs, symptoms, and risk factors of ovarian cancer, provide support to survivors, and raise funds for research in order to find a cure.
Due Dates: May 29 (OSR) Ι May 31 (Sponsor)
Amount & Project Period: Up to $50,000/yr.
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Links: T.E.A.L. ® Beneficiaries Ι Application
P50 NCI

May 31 (LOI) See Below Federal NCI Provocative Questions

Revision Application to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCI's Provocative Questions (Clinical Trial Optional)

This FOA invites revision applications from currently funded NCI P50 Program Projects. Revision applications are expected to focus on research related to one of the 12 NCI Provocative Questions (PQs) published in RFA-CA-18-019 and RFA-CA-18-020 intended for new R01 and R21 applications, respectively.  Studies proposed in revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P50 award.  To be responsive, each application must specifically address a particular scientific problem identified as one of the PQs.
Due Dates: May 31 (Letter of Intent, Optional)
Applications Due:  June 27 (OSR) June 29 (Sponsor)
Additional Due Date: Oct. 30th
Amount & Project Period: May not exceed $150,000 /yr. (Direct Costs) for up to two (2) years, not to exceed remaining number of years on parent grant
Eligibility: NCI P50 research grants with at least two (2) years of support remaining on parent grant at estimated time of award;
PI (or Contact PI for multi- PI awards) on parent award must remain the same on a revision application;
Parent grant must be active when application is submitted. If a no-cost extension is needed on parent grant, it must be in place before revision application is submitted
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA-CA-18-024
Companion RFAs: RFA-CA-18-021, R01 Research Project Grant
RFA-CA-18-022, U01 Research Project - Coop. Agreement
RFA-CA-18-023, P01 Research Program Projects
John and Maria Laffin Trust

NEW
May 31 All Ranks Non-federal Multiple

John and Maria Laffin Trust
Research Grants

The Foundation awards grants for medical research that does not exclude from consideration any alternative or seemingly radical and/or controversial treatment which the American Medical Association may currently oppose.
Due Dates: May 29 (OSR) Ι May 31 (Sponsor)
Additional Due Date:  Oct. 31
Note:  Applications accepted year-round and reviewed at semi-annual grant meetings in July and November.
Amount & Project Period: Average awards range from $2,000 to $40,000
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: John and Maria Laffin Trust

NEW
June 04 (LOI) Junior faculty Non-federal Career Development

The Mark Foundation for Cancer Research
Emerging Leader Awards

These awards provide grant support to early career investigators conducting high-impact, high-risk cancer research. This award is intended to support projects for which other sources of funding are not readily available or for a separate innovative endeavor that will enhance the Principal Investigator's current research portfolio.
Due Dates: June 04 (Letter of Intent)
Invited Applications:  Jul. 16 (OSR) Jul. 18 (Sponsor)
Amount & Project Period: $750,000 (TOTAL) - 3 years
Eligibility: Must hold an MD, PhD, or equiv. and be 3 to 8 years from start of independent research appointment by December 31, 2018 (i.e., PI must have been appointed in 2015 or earlier, but no earlier than 2010);
Must have demonstrated ability to obtain independent funding for lab (e.g., 1 or 2 grants such as NIH/R01, NSF/CAREER, or equivalent multi-year awards);
Need not be a U.S. citizen but non-citizens must have appropriate visa or permanent resident status for such employment.
Contact: Office of Sponsored Research (x6804)
Links: The Mark Foundation for Cancer Research
Emerging Leader - Guidelines
Mark Foundation's online submission portal
R01 NCI

June 05 All Ranks Federal Tumor Monitoring

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (Clinical Trial Optional)

The purpose of this FOA is to support projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Due Dates: June 1 (OSR) Ι June 05 (Sponsor)
Additional Due Dates:  Standard dates
Amount & Project Period: MAX. $499,999/yr. (Direct Costs) - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-629
R01 NIH
NCI is a participating Institute
June 05 All Ranks Federal Gender Identity and Health

Research on the Health of Transgender and Gender Nonconforming Populations (Clinical Trial Optional)

This FOA calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other.
Due Dates: June 01 (OSR) Ι June 05 (Sponsor)
Additional Due Dates: Standard dates
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-729
Companion FOA: PA-18-728 (R21)
R01 NIH
NCI is a participating Institute
June 05 All Ranks Federal Treatment & Prevention Regimens

Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (Clinical Trial Optional)

This FOA calls for research applications addressing patient adherence to treatment and prevention regimens to promote health outcomes. NCI seeks multi-level research from across the translational science continuum aimed at improving adherence to treatment and prevention regimens to reduce cancer risk, improve treatment outcomes, and lower cancer-related morbidity, mortality, and disability. Additional information about priority areas of research are described by the NCI's Division of Cancer Control and Population Sciences.
Due Dates: June 01 (OSR) Ι June 05 (Sponsor)
Additional Due Dates: Standard dates
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-722
Companion FOA: PA-18-723 R21
R01 NCI

June 05 All Ranks Federal Tumor Cancer Therapy

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (Clinical Trial Optional)

NCI seeks grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Due Dates: June 01 (OSR) June 05 (Sponsor)
Additional Due Dates: Standard dates
Amount & Project Period: Limited to $499,999/yr. (Direct Costs) - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-629
R21 NIH
NCI is a participating Institute
June 07 All Ranks Federal Health Disparities

Exploratory/Developmental Surgical Disparities Research (Clinical Trial Optional)

The purpose is to encourage developmental and exploratory research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations.  The goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, while employing multi-level strategies at the institutional and systems level.  
Due Dates: June 05 (OSR) Ι June 07 (Sponsor)
Additional Due Date:  June 07, 2019
Amount & Project Period: $275,000 - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-289
Companion FOA: PAR-18-288  Surgical Disparities Research (R01 Clinical Trial Optional)

NEW
June 07, 3:00pm Postdocs Non-federal Career Development

amfAR
Mathilde Krim Fellowships in Basic Biomedical Research

To facilitate the exceptional postdoctoral researcher's transition to an independent career in HIV/AIDS research.
Due Dates: June 07, 3:00pm EDT (Registration for Portal Log-in and Forms (REQUIRED))
June 11, 2018, 3pm EDT (Letter of Intent)
Invited Applications:  Early August 2018 (tentative)
Amount & Project Period: $150,000/yr. - 2 years
Eligibility: Hold research or clinical doctorate completed bet. 3 and 6 years prior to May 3, 2018;
Positioned to secure an independent research position no later than March 2021;
Effort on Fellowship must be 85%;
Must be mentored by an experienced investigator at same institution who: (a) is qualified to oversee proposed research; (b) has successfully supervised postdoctoral fellows; and (c) is at associate professor level or higher.
(See Applicant Eligibility and Qualifications) for additional detail.
Grantee Institution must provide funds or in-kind support to enhance career development of fellow (mentoring program; reduced-rate use of core facilities; etc.).
Institution must provide support for attendance at an NIH grant-writing workshop, or a similar training activity approved in advance by amfAR.
Contact: Office of Sponsored Research (x6804)
Links: RFP Ι Registration & Forms
Admin. Supplement NIH
NCI is a participating Institute
June 08 See Below Federal Alzheimer's disease (AD) and Related dementias (ADRD)

Alzheimer's Disease and its related Dementias (AD/ADRD)-focused Administrative supplements for NIH grants that are not focused on Alzheimer's disease

Participating Institutes and Centers (ICs) invite applications to expand existing awards in these ICs that are not currently focused on Alzheimer's disease (AD) and its related dementias (ADRD) to allow them to develop a focus on AD/ADRD.  As part of the application investigators should submit an abstract of the proposed research that shows the relevance to AD/ADRD. The work may include pilot projects, or resource development. 
Due Dates: June 06 (OSR) Ι June 08 (Sponsor)
Amount & Project Period: $250,000 (Direct Costs) -  1 year
Eligibility: Active awards w/project end dates in FY19 or later are eligible. Award may not be in terminal no cost extension or going into no cost extension in FY18.
Contact: Office of Sponsored Research (x6804)
Link: NOT-AG-18-008
R01 NIH
Common Fund initiative Administered by NCI
June 09 (LOI) All Ranks Federal Druggable Genome

Cutting Edge Informatics Tools for Illuminating the Druggable Genome (Clinical Trial Not Allowed)  

The purpose of this FOA is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the Knowledge Management Center (KMC) as well as the broader Illuminating the Druggable Genome (IDG) Consortium.
Due Dates: June 09 (Letter of Intent, Required)
Applications Due: Jul. 05 (OSR) Ι Jul. 09 (Sponsor)
Amount & Project Period: Limited to $300,000/yr. (Direct Costs) - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA-RM-18-011


NEW
June 11 (Pre-application) All Ranks Non-federal Multiple Areas

Ferring Research Institute (FRI)
2018 Ferring Innovation Grants Program

FRI is interested in funding exploratory, discovery and preclinical research into novel drug targets with potential application in indications within core therapeutic areas:
--> Gastroenterology & Hepatology
--> Reproductive Medicine and Women's Health
--> Urology
--> Biomarker Discovery
Clinical studies and studies which require the collection of human samples under the direction of an Institutional Review Board are not supported.
The program will provide a limited number of research grants in the following categories: ·         ---> Exploratory grants: support feasibility studies that will confirm the target's role in the proposed indication.
--> Discovery grants: support further research on targets with existing in vitro data validating its utility in the proposed indication.  The planned research should provide data to support transferring the target to a drug discovery program.
--> Competitive Postdoctoral and Graduate Student Fellowships: support research in one of FRI's areas of interest.
Due Dates: June 11 (Pre-application) - A status notification will be sent
w/in 4 weeks,  and applicants must submit full applications w/in 4 weeks of status notification.
Amount & Project Period: $50,000 - $100,000 - 1 year
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Links: Ferring Innovation Awards Ι Areas of Interest Ι Portal


NEW
June 11 Junior Faculty Non-federal Biomedical Achievement

Vilcek Foundation
Vilcek Prizes For Creative Promise in Biomedical Science

The Vilcek Foundation will award prizes to young foreign-born biomedical scientists who demonstrate outstanding early achievement. Eligible work may be in basic, applied, and/or translational biomedical science.
Due Dates: June 11 (Sponsor)
Amount & Project Period: $50,000 cash prize
Eligibility: Must have been born outside the U.S.;
Must not be more than 38 years old as of December 31, 2018 (born on or after January 1, 1980);
Must be a naturalized citizen or permanent resident (green card holder) of the U.S.; be a holder of an H1B or O-1 visa and have been living and working in the U.S. for at least 5 years; or have been granted Deferred Action for Childhood Arrivals (DACA); Must have earned a doctoral degree (MD, PhD, or equiv.);
Must hold a full-time position at an academic institution or other organization. Eligible positions include: asst. or assoc. prof. or equiv. independent position;
Must be directly responsible for design and execution of work submitted for consideration;
Graduate students and postdocs working under supervision of a mentor are not eligible.
Contact: Shinnie Kim, Program Officer, at 212-472-2500 or creativepromise@vilcek.org.
Link: Vilcek Prizes


June 11 (LOI) All Ranks Non-federal Surgical Technology

Intuitive Surgical Technology
Research Grants

The purpose of these grants is to support technology research in the field of surgical robotics, or related fields. Successful proposals will address clinically-relevant technology development.
Due Dates: June 11 (Letter of Intent)
Invited Submissions:  Sept. 12 (OSR) Ι Sept. 14 (Sponsor)
Note that an invitation to submit will include application guidelines and forms.
Amount & Project Period: $10,000 to $50,000 - 1 year
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Links: Intuitive Surgical Research Grants Ι LOI Portal
R01 NCI
June 11 (LOI) All Ranks Federal Adducts/Adductomics

Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (Clinical Trial Not Allowed)

This FOA encourages research focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. Priority is on projects focusing on adductomic approaches, i.e., address some aspects of the totality of adducts. Projects should explore basic aspects of adducts/adductomics that may have  potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. 
Due Dates: June 11 (Letter of Intent, not required or binding)
Applications Due: Jul. 09 (OSR) Ι Jul. 11(Sponsor)
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-704
Companion FOAs: PAR-18-703, R21
PAR-15-307, U01
R01 NCI

June 13 All Ranks Federal Smoking Cessation

Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (Clinical Trial Optional)

This FOA is intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact.
Due Dates: June 11 (OSR) Ι June 13 (Sponsor)
Additional Due Dates:  Oct. 11 and June 13, 2019
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-251
Companion FOA: PAR-18-250  R21
R01 NCI
June 13 All Ranks Federal Cancer Communication

Innovative Approaches to Studying Cancer Communication in the New Media Environment (Clinical Trial Optional)

This FOA invites applications seeking to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life.
Due Dates: June 11 (OSR) Ι June 13 (Sponsor)
Additional Due Dates:  Oct. 11 and June 13, 2019
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-638
Companion FOA: PAR-18-639  R21


NEW
June 15 Junior Faculty Non-federal Neurobiology Prize

Eppendorf & Science Prize for Neurobiology

This Prize is intended to encourage and support the work of promising young neurobiologists. It is awarded annually to one young scientist for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years, as described in a 1,000-word entrance essay that is rated in two areas: scientific quality & significance, and clarity & writing style.
Due Dates: June 15 (Sponsor) Entry form and additional submission materials must be submitted electronically through the prize management system.
Prize Amount and Details: The winner receives:
Prize money of US$25,000;
Essay published in Science and on Science Online; ·       Complimentary 10-year AAAS Membership, a 10-year digital subscription to Science as well as US$ 1,000 in complimentary Eppendorf products;
Full support to attend Prize Ceremony held in conjunction with Annual Meeting of the Society for Neuroscience in the USA and Invitation to visit Eppendorf in Hamburg, Germany
Eligibility: Entrant must be a neurobiologist w/advanced degree received w/in last 10 years and not older than 35 years of age;
Entrant's essay must describe contributions to neurobiological research based on methods of molecular and cell biology; Entrant must have performed or directed work described in essay;
Research must have been performed during previous three years.
Contact: eppendorfscienceprize@aaas.org
Link: Overview
R21 NIH
NCI is a participating Institute
June 16 All Ranks Federal Obesity

Exploratory/Developmental Clinical Research Grants in Obesity (Clinical Trial Optional)

NCI is interested in fostering research focused on identifying effective interventions for the prevention and treatment of obesity, including novel energy intake and expenditure modalities that alter body weight and/or composition in certain subpopulations of cancer patients and those at high risk for cancer.
Due Dates: June 14 (OSR) Ι June 18 (Sponsor)
Additional Due Dates: Standard dates
Amount & Project Period: $275,000 (Direct Costs) - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-720
R21 NIH
NCI is a participating Institute
June 16 All Ranks Federal Patient Adherence

Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)

This FOA calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes.  NCI seeks multi-level research from across the translational science continuum aimed at improving adherence to treatment and prevention regimens to reduce cancer risk, improve treatment outcomes, and lower cancer-related morbidity, mortality, and disability. Additional information about priority areas of research are described by the NCI's Division of Cancer Control and Population Sciences.
Due Dates: June 14 (OSR) Ι June 18 (Monday, Sponsor)
Additional Due Dates: Standard dates
Amount & Project Period: $275,000 (Direct Costs) - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-723
Companion FOA: PA-18-722 R01
R21 NIH
NCI is a participating Institute
June 16 All Ranks Federal Gender identity

Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)

This FOA calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other.
Due Dates: June 14 (OSR) Ι June 18 (Monday, Sponsor)
Additional Due Dates: Standard dates
Amount & Project Period: $275,000 (Direct Costs) - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-728
Companion FOA: PA-18-729  R01
R01 NIH
NCI is a participating Institute
June 17 (LOI) All Ranks Federal Substance Abuse

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (Clinical Trial Optional)

As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose is to support development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.
Due Dates: June 17 (Letter of Intent, not required or binding)
Applications Due:  Jul. 13 (OSR) Ι Jul. 17 (Sponsor)
Additional 2018 Due Date: Nov. 13
Amount & Project Period: Max. $500,000/yr. (Direct Costs) - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-222
Companion FOA: PAR-18-223 R34 (Planning Grant)
R01 NIH
NCI is a participating Institute
June 19 Junior/Early Stage Investigators Federal Basic Cancer Research/Diversity

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (Clinical Trial Not Allowed)

The purpose is to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible junior investigators and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This funding opportunity will also provide a bridge to investigators who have completed their research training and may need extra time to develop a larger research project grant application.
Due Dates: June 15 (OSR) Ι June 19 (Sponsor)
Additional Due Dates: Nov. 19, 2018; & June 18, Nov. 19, 2019
Amount & Project Period: $275,000 (Direct Costs) - 2 years
Eligibility: Junior and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical workforce;
Current or former PIs of an NIH R03 or R21 grant, or a non-federal equivalent to an R03 or R21 grant are eligible, but current or former PIs on an NIH research project grant (such as an R01), or any peer-reviewed non-NIH research grant over $175,000 direct costs/year are not eligible);
An individual may receive no more than 2 awards from the Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research program, including past and future iterations of this FOA;
By the time of award, PI must be a citizen or a non-citizen national of the U. S. or have been lawfully admitted for permanent residence (i.e., possess a currently valid Permanent Resident Card USCIS Form I-551, or other legal verification of such status).
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-731

NEW
June 20 (Pre-application) All Faculty Ranks Federal Multiple

Congressionally Directed Medical Research Programs
Peer Reviewed Cancer Research Program (PRCRP)

 
Due Dates: June 20 (Pre-application)
Invited Applications:  Sept. 24 (OSR) Ι Sept. 26 (Sponsor)
Contact: Office of Sponsored Research (x6804)
Primary Links: PRCRP Funding Opportunities
General Application Instructions/Version 20180329
Note: The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at http://orcid.org/ 
CDMRP-PRCRP

Impact Award
W81XWH-18-PRCRP-IPA

This award supports hypothesis-driven, high-impact research. It encourages applications specifically focused on critical scientific and clinical cancer issues.  Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples and trials.  Note:  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, or ovarian cancer will not be accepted.  Please review the FY18 PRCRP Topic areas in the funding announcement.
Amount & Project Period: $1,000,000 (Direct Costs) - 3 years
Eligibility: Independent investigators at or above Asst. Professor (or equiv.) level;
Each PI may submit only one FY18 PRCRP Impact Award pre-application
Link: W81XWH-18-PRCRP-IPA
CDMRP-PRCRP

Idea Award with Special Focus
W81XWH-18-PRCRP-IASF  

This award supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. The proposed research should be innovative and not progression of an already established project.  Therefore, no preliminary data is needed.
Amount & Project Period: $400,000 (Direct Costs) - 2 years
Eligibility: PI must have a faculty level appointment (or equiv.)
Each PI may submit only one application
Link: W81XWH-18-PRCRP-IASF
CDMRP-PRCRP

Translational Team Science Award
W81XWH-18-PRCRP-TTSA

This award supports hypothesis-driven translational studies. Studies should be associated with a clinical trial and/or existing annotated biorepositories. Proposed project should focus on research for the next-phase clinical trial or future clinical application.  The award is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the award is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial.
Amount & Project Period: $1,000,000 (Direct Costs) - 4 years
Eligibility: Initiating PI must be at or above Asst. Professor Level or equiv.; Partnering PI(s) must be at or above Asst. Professor or equiv.;
It is encouraged that at least one of the PIs be a military or VA investigator.
Link: W81XWH-18-PRCRP-IASF
K01 NIH
NCI is a participating institute
NEW
June 20 (LOI) Faculty Ranks Federal Career Development

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (Independent Clinical Trial Not Allowed)

The purpose is to provide support and protected time for an intensive, supervised career development experience in biomedical, behavioral, and social science research. Research projects must address research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.
Due Dates: June 20 (Letter of Intent, not required or binding)
Jul. 17 (OSR) Ι Jul. 19 (Sponsor)
Addnl. Due Dates:  Nov. 08; Jul. 19 & Nov. 08, 2019 (Subsequent Letter of Intent due dates are 60 days prior to due date.  
Amount & Project Period: Up to $ 90,000/yr. (Direct Costs) toward salary of recipient and $60,000/yr. (Direct Costs) for research development costs - 5 years
Eligibility: Must have research or health-professional doctoral degree;
Must have full time appt. and commit 75% effort to career development activities during mentored phase;
Must be citizen or non-citizen national of U.S. or have been lawfully admitted for permanent residence;
Current & former PDs/PIs on R01, P01, P50, sub-projects of P01 or P50, other major individual career development awards (e.g., K awards), or equiv. are not eligible.
Current & former PDs/PIs on NIH R03, R21, R36, or SBIT/STTR awards remain eligible.
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA-OD-18-005
Companion RFAs: RFA-OD-18-006, K01 Research Scientist Development Award - Research & Training (Independent Clinical Trial Required);
RFA-OD-18-007, K99/R00 Career Transition Award/Research Transition (Clinical Trial Not Allowed);
RFA-OD-18-008 K99/R00 Career Transition Award/Research Transition (Independent Clinical Trial Required) 
June 20 See Below Non-federal Women's Cancers

The Foundation for Women's Wellness
2018 Awards

Due Dates: June 18 (OSR) Ι June 20 (Sponsor)
Contact: Office of Sponsored Research (x6071)
Primary Link: Foundation for Women's Wellness
 

2018 Research Awards

These research awards target early funding for small, short-term studies that hold promise for improving medical knowledge in leading female cancers.  Applications should only be for studies that are exploring basic, clinical or epidemiological lines of inquiry.
Amount & Project Period: $25,000 - 1 year
Eligibility: Must be an M.D. and/or Ph.D. with a faculty appointment (assistant professor, or higher)
Link: Research Awards
 

2018 Fellowship Awards

Fellowship Awards recognize and support MD/PhD candidates or graduates pursuing fellowship or specialty training and working on research in women's health. Research focus is on focus is on basic, clinical or epidemiological lines of inquiry.
Due Dates: June 20 (Submit directly to sponsor)
Amount & Project Period: $25,000 - 1 year
Eligibility: Must be currently and/or be pursuing an MD and/or PhD and must still be in process of completing education or medical training (specialty training, fellowship);
Applicants must have a social security number. Award checks go directly to individuals and will be reported to the IRS as required by federal law
Link: Fellowship Awards

Upcoming Cycle 2
June 21 (LOI) All Ranks Federal PCOR

Patient Centered Outcomes Research Institute (PCORI)
Implementation of PCORI-Funded Patient-Centered Outcomes Research Results -- Cycle 2 2018

This PCORI Funding Announcement will open on Friday, June 1, 2018. Preliminary details are provided below. More information will be posted here as the open date approaches.
Due Dates: June 21 (Letter of Intent)
Applications Due:  Aug. 28 (OSR) Ι Aug. 30 (Sponsor)
Amount & Project Period: $750,000 (Direct Costs) - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: Funding Announcement
R01 NIH
NCI is a participating Institute
June 21 All Ranks Federal Image-guided Drug Delivery

Image-guided Drug Delivery (Clinical Trial Optional)

This FOA will support innovative research projects focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.
Due Dates: June 19 (OSR) Ι June 21 (Sponsor)
Additional 2018 Due Date:  Nov. 22nd
Amount & Project Period: Application budgets are not limited - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-252


NEW
June 26 (Pre-app.) See Below Federal Lung

Congressionally Directed Medical Research Programs
Lung Cancer Research Program (LCRP)

Due Dates: June 26 (Pre-application)
Invited Applications:  Sept. 24 (OSR) Ι Sept. 26 (Sponsor)
Contact: Office of Sponsored Research (x6804)
Primary Links: LCRP Funding Opportunities
General Application Instructions/Version 20180329
Note: The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at http://orcid.org/.
LCRP

Idea Development Award
W81XWH-18-LCRP-IDA

This award promotes new ideas still in the early stages of development and having potential to yield impactful data and new avenues of investigation. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.  Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.
Amount & Project Period: $350,000 - 2 years  
Eligibility: Established Investigators must be independent, and at or above Asst. Professor (or equiv.) level;
New Investigators must be w/in 10 years of first faculty appointment (or equiv.) at application submission deadline; Must not have previously received an LCRP Idea Development Award or LCRP Early Investigator Synergistic Idea Award
Link: W81XWH-18-LCRP-IDA
LCRP

Investigator Initiated Translational Research Award
W81XWH-18-LCRP-IITRA

This award supports translational research that will develop promising ideas in lung cancer into clinical applications. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. Preliminary data to support feasibility of research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.
Amount & Project Period: $400,000 - 2 years
Eligibility: PI must be at or above Asst. Professor (or equiv.) level
Link: W81XWH-18-LCRP-IITRA
LCRP

Translational Research Partnership Award
W81XWH-18-LCRP-TRPA

This award supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty level (or equivalent) investigators to address a central problem or question in lung cancer in a manner that would be less readily achievable through separate efforts.
Amount & Project Period: $900,000 - 3 years
Eligibility: Requires 2 PIs (Initiating and Partnering);
PIs must be at or above Asst. Professor (or equiv.) level;
One partner must be a research scientist and the other must be a clinician; and at least 1 member of partnership must have experience either in lung cancer research or lung cancer patient care;
Clinician must be MD, MD/PhD., or equiv. w/clinical duties and/or responsibilities;
Note:  Multi-institutional applications must include an intellectual property plan.
Link: W81XWH-18-LCRP-TRPA

Upcoming Cycle 2
June 28 (LOI) All Ranks Federal PCOR

Patient-Centered Outcomes Research Institute
Broad PCORI Funding Announcements -- Cycle 2 2018 (for Addressing Disparities, Assessment of Options, Communication and Dissemination Research, Improving Healthcare Systems)

This PCORI Funding Announcement will open on Friday, June 1, 2018. Preliminary details are provided below. More information will be posted here as the open date approaches.

The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with priority research areas. This PFA covers 4 priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research; and Improving Healthcare Systems.
Due Dates: June 28 (Letter of Intent)
Applications Due:  Sept. 21 (OSR) Ι Sept. 25 (Sponsor)
Amount & Project Period: $750,000 (Direct Costs) - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: Funding Announcement

Upcoming Cycle 2
June 28 (LOI) All Ranks Federal PCOR

Patient Centered Outcomes Research Institute (PCORI)
Improving Methods for Conducting Patient-Centered Outcomes Research -- Cycle 2 2018

This upcoming funding announcement (PFA) will be released by PCORI on June 1st.

Projects are sought that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by PCOR/CER studies. For the Cycle 2 2018 Methods PFA, PCORI has identified the following Research Areas of Interest (RAIs) as programmatic priorities:
Methods Related to Ethical and Human Subjects Protections (HSP) Issues in PCOR/CER;
Methods to Improve Study Design;
Methods to Support Data Research Networks; and
Methods to Improve the Use of Natural Language Processing
Due Dates: June 28 (Letter of Intent)
Applications Due:  Sept. 21 (OSR) Ι Sept. 25 (Sponsor)
Amount & Project Period: $750,000 (Direct Costs) - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: Funding Announcement

June 29 All Ranks Non-federal General Cancer Research

Phi Beta Psi Sorority
Annual Research Grant Award (Florida Grant)
(MCC Foundation-facilitated)

Phi Beta Psi's goal is to advance cancer research nationwide, and grants are awarded only to investigators submitting applications addressing the basic and clinical studies in the field of cancer.
Due Dates: June 27 (OSR) Ι June 29 (Sponsor)
Amount & Project Period: $20,000 - 1 year
Eligibility: All Ranks
Contact: Suzanne Knapp, Moffitt Foundation, (x1400)
Link: How to Apply


NEW
June 30 All Faculty Ranks Non-federal Children's Leukemia

Children's Leukemia Research Association (CLRA)
Research Grants

Grants for the conduct of research into leukemia.  Funding shall not duplicate other funding sources.
Due Dates: June 28 (OSR) Ι June 30 (Sponsor)
Amount & Project Period: All Faculty Ranks
Eligibility: $30,000 -1 year
Contact: Office of Sponsored Research (x6804)
Link: Overview and Application
Admn. Supplement NCI

NEW
June 30 See Below Federal Drug Resistance/Sensitivity

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Clinical Trial Not Allowed)

As part of the Cancer Moonshot initiative, the NCI created the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (supported by U54 cooperative agreement awards) focused on using advanced techniques and models to accelerate understanding of issues of cancer resistance or extreme sensitivity to anticancer agents.
This FOA provides supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-U54 investigators and DRSN U54-supported investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials.
Due Dates: June 28 (OSR) Ι Jul. 02 (Sponsor)
Amount & Project Period: $250,000 (TOTAL) - 1 year Note: budget should not include the estimated expenses of the collaborating Drug Resistance and Sensitivity Center (DRSC)
Eligibility: Project and budget periods must be within the currently approved project period for the existing parent award.  Administrative supplement requests must be submitted on paper for the following activity codes: P01 Research Program Projects; P30 Center Core Grants; P50 Specialized Center; U54 Specialized Center- Cooperative Agreements; and UM2 Program Project or Center with Complex Structure Cooperative Agreement Administrative supplement requests may be submitted electronically for the following activity codes: R01 Research Project Grant; U01 Research Project – Cooperative Agreements; and UM1 Multi-Component Research Project Cooperative Agreements
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-752

NEW
Restricted Submission
June 30 (Pre-app.) Junior Faculty Non-federal Hematologic Malignancies

Gabrielle's Angel Foundation for Cancer Research
Research Grants
                                    ***Restricted Submission***

Gabrielle's Angel Foundation for Cancer Research has announced two funding opportunities for cancer research projects to address fundamental problems in the genesis and treatment of blood related cancers.  Moffitt can nominate two junior research investigators: one conducting mainstream or conventional research, and one conducting complementary or integrative research.  
Due Dates: June 30 (Pre-application)
Pre-Application must include a 1-page letter of introduction and a 2-page outline submitted in PDF format only via email to Maureen Ahearn
Selected applications:  Aug.15 (OSR) Ι Aug. 17 (Sponsor)
Amount & Project Period: $75,000/yr. - 3 years
Eligibility: Must have an MD or PhD;
Must hold junior faculty position, and have held current position for no longer than 5 years;
Must hold designation of Asst. Professor (Assoc. Professors may not apply);
Must have tenure track position;
Must have independent research projects, independent resources and preliminary results and/or publications from their independent laboratory.
Contact: Maureen Ahearn (x8824) for guidelines
Links: FAQs Ι Integrative Medicine Information



NEW
July 01 All Ranks Non-federal Clinical Oncology

SWOG Early Exploration and Development (SEED) Fund

This fund encourages preliminary research to potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the National Clinical Trials Network (NCTN).  Awards may assist investigators with projects supporting the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology.
Due Dates: June 29 (OSR) Ι Jul. 01 (5:00, pm ET) (Sponsor)
Additional Due Date:  Dec. 01, 2018
Amount & Project Period: Up to $50,000 (Direct Costs) - 1 to 2 years
Eligibility: Any SWOG investigator eligible for NIH funding
Contact: Office of Sponsored Research (x6804)
Links: Overview Ι 2018 RFA
Admin. Supplement NCI
July 01 See Below Federal Data Sharing

Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Clinical Trial Not Allowed)

The purpose is to provide support to prepare and deposit individual-level data from cancer epidemiology studies into NIH/NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP).  Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.
Due Dates: June 28 (OSR) Ι July 02 (Sponsor)
Amount & Project Period: $150,000 (Total Costs) - 1 year Requests for no-cost extensions for parent grant to accommodate a supplement are not permitted.
Eligibility: Supplement available for existing projects with P01, U19, R01, U01 or UM1 activity codes;
Parent award must be active;
Project/budget periods must be w/in currently approved project period of existing parent award. 
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-748

July 01 All Ranks Non-federal Fibrolamellar Hepatocellular Carcinoma

Fibrolamellar Cancer Foundation
Research Grants

Research must focus on Fibrolamellar Hepatocellular Carcinoma. Studies should be intended to advance knowledge in the areas of FL-HCC. Of particular interest are those showing a clear path to clinical trials. Collaboration and open sourcing is a requirement for FCF funding and will be so specified in any grant agreement.
Due Dates: June 28 (OSR) Ι Jul. 01 (Sponsor)
Additional Due Date: Jan. 01
Note:  FCF is open to time sensitive requests - particularly for truly innovative ideas - throughout the year, as exceptions.
Amount & Project Period: Application must reflect true amount necessary to conduct project.  Duration is project dependent.  If a multi-year grant is requested, FCF reserves the right not to continue funding after year one if insufficient advancements have been made and/or reporting protocol is not followed. 
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: Apply for a Grant Ι Click here for Research Grant Application
Admn. Supplement NCI

NEW
July 01 See Below Federal Data Sharing

Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Clinical Trial Not Allowed)

This supplement will provide support to prepare and deposit individual-level data from cancer epidemiology studies into NIH/NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Datasets from all types of observational cancer epidemiology studies, as well as partial datasets that complement or critically update previously shared data, will be considered.
Due Dates: June 28 (OSR) Ι Jul. 02 (Sponsor)
Amount & Project Period: $150,000 (TOTAL) - 1 calendar year
Eligibility: Project and budget periods must be w/in currently approved project period for existing parent award;
Projects must be able to be completed w/in 1 calendar year; Requests for no-cost extensions on parent grant to accommodate a supplement will not be permitted.
Administrative supplement requests must be submitted on paper for the following activity codes: P01 Research Program Projects and U19 Research Program – Cooperative Agreements; Administrative supplement requests may be submitted electronically for the following activity codes: R01 Research Project Grant; U01 Research Project – Cooperative Agreements; and UM1 Multi-Component Research Project Cooperative Agreements
Contact: Office of Sponsored Research (x6804)
FOA Link: PA-18-748

NEW
July 02 Postdocs Non-federal Career Development

The Helen Hay Whitney Foundation
2018 Research Fellowship

This fellowship supports early postdoctoral research training in all basic biomedical sciences.
Due Dates: June 28 (OSR) Ι July 02 (Sponsor)
Amount & Project Period: Yr. 01:  $54,000 (Stipend) + $1,500 (Allowance)
Yr. 02:  $57,000 (Stipend) + $1,500 (Allowance)
Yr. 03:  $60,000 (Stipend) + $1,500  (Allowance)
Eligibility: Must have obtained or be in final stages of obtaining a PhD, MD, or equiv.;
Must not have more than 1 year of postdoctoral research experience at submission deadline and received a PhD (or D.Phil. or equiv.) no more than 2 years before deadline, or MD degree no more than 3  years before deadline;
No more than one application from a laboratory during each annual cycle.  Applications from different laboratories/supervisors at the same institution are allowed;
For research in US labs only; foreign students  must hold appropriate visa documentation as required by US immigration.
Contact: Office of Sponsored Research (X6804)
Link: Research Fellowships



NEW
July 02 (LOI) Established Investigators Non-federal Lymphoma

American Association for Cancer Research (AACR)  Stand-Up-To-Cancer
T-Cell Lymphoma Dream Team Translational Research Grant

This grant will fund a translational cancer research project focused on T-cell lymphoma that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.
Due Dates: Jul. 02 (Letter of Intent)
Invited Applications:  Oct. 10 (OSR) Ι Oct.12 (Sponsor)
Amount & Project Period: $8,000,000 - 3 years
Eligibility: Each Team will consist of a Dream Team Leader, a Dream Team Co-leader, no more than 4 additional Dream Team Principals, a Dream Team Project Manager, and at least 2 Advocates, w/no more than 6 but a minimum of 3 participating institutions;
Dream Team Leader, Co-leader and Principals must have acquired a doctoral or medical degree, and must be independent investigators;
Dream Team Leader and Co-leader are expected to each dedicate at least 20% (or 40% combined) effort;
Questions about eligibility requirements may be directed to the AACR SRGA Office at su2c@aacr.org prior to proposal submission  
Contact: Office of Sponsored Research (x6804)
Links: Funding Opportunity Detail
proposalCENTRAL  (Submission Site)
 
July 02, 12:00pm
(EDT) (LOI)		 Established
Investigators		 Non-federal Pediatric Brain
Cancer

NEW

SU2C-CRUK
Pediatric Brain Cancer Dream Team Translational Research Grant

The Dream Team will address critical problems in pediatric (age range up to 18 years) brain cancer treatment and positively impact patients in the near future. The project will accelerate the development of prevention strategies, diagnostic approaches or treatments for pediatric brain cancers through investigation by a collaborative multidisciplinary, multi-institutional, transatlantic Dream Team. The project must be designed to accelerate therapeutic application to the clinic with patient involvement within 4 years of the grant term.
Due Dates: Jul. 02 (Letter of Intent)
Applications Due: Aug. 09 (OSR) Ι Aug. 13, 12:00pm (EDT) (Sponsor)
Amount & Project Period: $10M - 4 years
Eligibility: Each Team will consist of a Dream Team Leader (DTL), a Dream Team Co-leader (DTC), no more than four additional Dream Team Principals (DTP), a Project Manager, and at least two Patient Advocates, with a minimum of three participating institutions;
The DTL, DTCs and DTPs, must have doctoral or medical degree and be independent investigators;
The DTL and DTCs are expected to each dedicate at least 20% (or 40% combined) time and effort;
DTPs must devote at least 10% time and effort;                              There are no citizenship or residency status restrictions for team members; See Program Guidelines for additional requirements
Contact: Office of Sponsored Research (x6804)
Link: Call for Applications


NEW
July 02 See Below Non-federal Lung

Lung Cancer Research Foundation (LCRF)
Research Grants

The LCRF grant program provides funding for innovative research focused on prevention, diagnosis, treatment and cure of lung cancer.  Applications are encouraged for projects investigating research topics such as: 
   Improving understanding of lung cancer biology;
   Prevention & screening for early detection;
   Identification of new biomarkers and development of targeted therapies;
   Development of more effective and safer therapies;
   Psychosocial research including supportive measures for people w/lung cancer and their
   families; and
   Quality of care and outcomes research for improvement of healthcare standards and overall
   patient outcomes.
Due Dates: June 28 (OSR) Ι Jul. 02 (Sponsor)
Amount & Project Period: $150,000 (TOTAL) - 2 years
Eligibility: Students and fellows
Young & mid-career investigators w/<10 years' experience since initial faculty appointment;
Non-tenure track researchers, staff scientists, and clinicians (any number years of experience)
Note:  Senior investigators w/>10 years' experience since faculty appointment are generally not eligible
Contact: Office of Sponsored Research (x6804)
RFA Link: RFP Ι 2108 Grant Application

July 06 Faculty Ranks Non-federal Career Development

Damon Runyon Cancer Research Foundation
Innovation Award

The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances.
Due Dates: Jul. 03 (OSR) Ι Jul. 06 (Sponsor)
Amount & Project Period: $300,000 - 2 years (A Stage 1 award will be for two years; 
Stage 2 support for years three and four will be granted to those awardees who demonstrate progress on their proposed research during years one and two of the award.)
Eligibility: Applicants must belong to one of the following categories: Tenure-track Asst. Professor w/in first 4 years of obtaining initial Asst. Professor position. (Cut-off date: July 1, 2013); Clinical Instructors and Senior Clinical Fellows (in final year of sub-specialty training) holding an MD and pursuing a period of independent research before taking a tenure-track faculty position, and must have dedicated laboratory space and support of institution;
Not eligible are Research Assistant Professors, Research Associate Professors, Research Scientists and Postdoctoral Fellows; 
Applicants are expected to commit at least 80% full time effort to conducting research.
See award overview for additional eligibility details.
Contact: Office of Sponsored Research (x6804)
Links: Award Overview Ι Application Guidelines

July 09 All Ranks Non-federal Cutaneous

American Society for Dermatologic Surgery
Cutting Edge Research Grant Program (CERG)

Submission of well-conceived research projects that stimulate advancement of the practice of dermatologic surgery, the invention of new technologies or research projects that document the outstanding and high volume work of dermatologic surgeons are encouraged. Examples of Board-directed topics include:  demonstration of patient satisfaction levels following treatments for skin cancer or cosmetic issues; demonstration of patient satisfaction levels following treatments for skin cancer by dermatologists vs. other medical specialties; efficacy of screenings in diagnosing skin cancer, for example, evidence-based outcomes of cancer cure/life span/quality of life in screened patients vs. un-screened patients. 
Due Dates: Jul. 05 (OSR) Ι Jul. 09(Sponsor)
Amount & Project Period: $20,000  
Eligibility: All Ranks
PD/PI must be ASDS member
Contact: Office of Sponsored Research, x6804
Links: Overview Ι Application Site
R44/SBIR Phase IIB NCI

NEW
July 14 (LOI) See Below Federal Cancer-focused Technologies

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization (Clinical Trial Optional)

Funding under this FOA provides additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage.
Due Dates: Jul. 14 (Letter of Intent, not binding or required)
Aug. 13 (OSR) Ι Aug. 15 (Sponsor)
Amount & Project Period: For any single year of the project period, budgets up to $2,000,000 (total costs) may be requested. Combined budget for entire project period must not exceed $4,000,000 (total costs). - 3 years
Eligibility: Small Business Concerns (SBCs
Primary employment of PD/PI must be w/small business concern at time of award and during conduct of proposed project. For projects w/multiple PDs/PIs, at least one must meet primary employment requirement. Occasionally, deviations from this requirement may occur.
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA-CA-18-011


July 15 Postdocs Non-federal Research Award

Science & SciLifeLab Prize for Young Scientists

Recent doctoral graduates in the life sciences may submit a 1,000-word essay based on their thesis work. Four winners - in the categories of Cell and Molecular Biology, Ecology and Environment, Genomics and Proteomics and Translational Medicine - will be selected for this international award.
Due Dates: Jul. 15 (Sponsor)
The winners will: Have their essay published by Science;
$30,000 Grand Prize Winner; $10,000 ea. category winner;
Be honored in Stockholm, Sweden in December.
Eligibility: Entrants for the 2018 prize must have been awarded their Ph.D. between January 1 2016 and December 31 2017;
Prize will only recognize work that was performed while the entrant was a graduate student
Contact: SciLifeLabPrize@aaas.org
Links: Overview | How to Enter


NEW
July 16 (Pre-application) All Faculty Ranks Federal Bone Marrow Failure

Congressionally Directed Medical Research Programs
Bone Marrow Failure Research Program (BMFRP)
Idea Development Award
W81XWH-18-BMFRP-IDA

This award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence toward a vision of understanding and curing BMF diseases. This award mechanism is designed to support new ideas, and proposed research studies should have a high probability of revealing new avenues of investigation.
Due Dates: Jul. 16 (Pre-application)
Invited Applications:  Oct. 30 (OSR) Ι Nov. 01 (Sponsor)
Amount & Project Period: $325,000 (Direct Costs) - 2 years
Eligibility: Established Investigator:
At or above Asst. Prof. (or equiv.) level, and  10 years or more from  terminal degree;
Should have BMF disease-related expertise and background demonstrated by funding and publication records;
Early Career Investigator:
At Asst. Prof., Instructor, or Asst. Research Prof. (or equiv.) level, and less than 10 years from terminal degree (excluding time spent in medical residency or during family medical leave, which is to be clearly articulated by applicant in biographical sketch);
Institutional commitment such as, but not limited to, independent laboratory space, dedicated research time, and potential collaborations should be demonstrated.
Postdoctoral fellows are not eligible to apply as ECIs.
Contact: Office of Sponsored Research (x6804)
Links: FY18BMFRP Ι W81XWH-18-BMFRP-IDA
R01 NCI
NEW
July 18 (LOI) All Ranks Federal Kaposi Sarcoma (KS)

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (Clinical Trial Optional)

The purpose is to advance understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV.
Due Dates: Jul. 18 (Letter of Intent, not required or binding)
Applications Due: Aug. 14 (OSR) Ι Aug. 16 (Sponsor)
Amount & Project Period: Budgets may not exceed $500,000/yr. (Direct Costs) - 5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA-CA-18-013
Companion RFA: RFA-CA-18-014 (R21)

July 20 Postdocs & Junior Faculty Non-federal Career Development/Breast

Breast Cancer Alliance
Young Investigator Grants

This award is intended for young researchers without their own major grant support to encourage a commitment to breast cancer research. Areas of relevant research may be, but not limited to, diagnosis, etiology, immunology, genetics, therapies, prevention, and clinical studies.
Due Dates: Jul. 18 (OSR) Ι Jul. 20 (Sponsor)
Amount & Project Period: $125,000 - 2 years
Eligibility: Must have held faculty position for no more than 4 years after completion of training as of 02/01/2019;
Must not have been a PI on an NIH R01 or equivalent national/international non-mentored award;
Must dedicate at least 50% effort to research;
Current postdocs are eligible if they meet all the other stated criteria for young investigators.
Contact: Office of Sponsored Research (x6804)
Link: How to Apply


NEW
July 20 All Ranks Non-federal Radiation Oncology

Radiation Oncology Institute
2018 ROI Publication Award

The ROI Publication Award recognizes the best scientific work in one of the priority areas for radiation oncology that form the ROI's research agenda: communication, safety and quality, toxicity management, comparative effectiveness and value. Using either qualitative or quantitative techniques, articles may present, analyze, and comment on new data, or may synthesize and analyze data that have already been collected.
Due Dates: Jul. 18 (OSR) Ι Jul. 20 (Sponsor)
Amount & Project Period: Lead author will receive a $5,000 grant to be used on research that will build upon the work in the award-winning manuscript. Funds may be used to support project staff salaries and benefits, consultant fees, data management, supplies and other direct expenses. Award presented at 2018 ASTRO Annual Meeting in San Antonio, Texas.
Eligibility: Articles must have been published in a peer-reviewed journal w/a publication date between July 1, 2017, and June 30, 2018 Nominator must be a member of the American Society for Radiation Oncology (ASTRO). Self-nominations are accepted.
Contact: Office of Sponsored Research (x6804)
RFA Link: Guidelines Ι ROI portal on proposalCENTRAL

NEW
July 24 (LOI) All Ranks Federal PCOR

Patient Centered Outcomes Research Institute (PCORI)
Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 2 2018  

 This PCORI Funding Announcement will open on Thursday, June 28, 2018. Preliminary details are provided below. More information will be posted here as the open date approaches.

This advance notice provides revised eligibility requirements for projects proposed in response to this PCORI Funding Announcement (PFA).  Applicants proposing to implement results of a PCORI-funded study who are not the original PI of that study are no longer required to submit a Letter of Support from the PCORI study's original PI. To be eligible, applicants may either a) propose to implement a shared decision making (SDM) strategy that was formally tested and demonstrated to be effective in the context of a PCORI research award, or b) propose an implementation project that will incorporate new PCORI CER evidence into an existing, tested shared decision making strategy, and then implement the updated shared decision making strategy.
Due Dates: Jul. 24 (Letter of Intent)
Applications Due:  Oct. 08 (OSR) Ι Oct. 10 (Sponsor)
Amount & Project Period: $1.5M (Direct Costs) - 3 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Link: Funding Announcement

NEW
July 25 (Pre-app.) See Below Federal Ovarian

Congressionally Directed Medical Research Programs
Ovarian Cancer Research Program
FY2018 Funding Opportunities

Due Dates: Jul. 25 (Pre-application)
Applications Due:  Aug. 06 (OSR) Ι Aug. 08 (Sponsor)
Contact: Office of Sponsored Research (x6804)
RFA Link: FY18 Ovarian Cancer Research Program (OCRP)
Program Funding Opportunities Ι Application Instructions
Note: The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at http://orcid.org/.
 

Clinical Development Award
W81XWH-18-OCRP-CDA

The goal is to accelerate clinical introduction of medical products and technologies that target ovarian cancer biology. Near-term clinical impact is expected. Preclinical studies in animals are not allowed. Small-scale clinical trials (Phase 0, Phase 1), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed. Relevant data, either published or unpublished, that support the study rationale are required. This mechanism offers an optional nested Early-Career Investigator (ECI). One ECI can be named in a given application.
Amount & Project Period: $600,000 (Direct Costs)  - 3 yrs. 
Note:  W/nested ECI:  $800,000 (Direct Costs) - 3 yrs.
Eligibility: Independent investigators at or above the level of Assistant Professor (or equiv.);
Nested Early-Career Investigator (ECI)
ECI must be w/in 5 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent at full application submission deadline;
PI on the Clinical Development Award must mentor nested ECI;
ECI can only be selected if clinical trial is being proposed; and Eligibility letter is required w/submission of full application.
Link: W81XWH-18-OCRP-CDA
 

Omics Consortium Development Award
W81XWH-18-OCRP-OMCDA  

The FY18 OMCDA supports a multi-institutional research effort  that specifically focuses on the compilation of new and/or use of existing large datasets to study the origin of ovarian cancer disease with an emphasis on early detection and screening.  This will be executed through a 2-stage approach using 2 separate award mechanisms: the first is this FY18 OMCDA, which will enable a consortium to lay groundwork for the research project, including a proof of concept preliminary research project.
Research projects proposed must use large datasets (genomics, proteomics, metabolomics, other ‘omics) to focus on origin of disease. The long-term goal is to facilitate improvements in early detection and screening of ovarian cancer, although immediate benefits of the consortium will be in initial diagnosis and therapy. Applicants are encouraged to include rare subsets and putative pre-malignant lesions, as well as linkage to relevant interventional clinical trials, to be included in the data gathered by the OMCDA.
Amount & Project Period: $400,000 - 2 yrs.
Eligibility: PIs must be independent investigators at Assoc. Prof. level (or equiv.) or higher;
Research team must include at least one Early-Career Investigator (defined as an investigator w/in 5 years of last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equiv.), at least one ovarian cancer consumer advocate, and at least one Epidemiologist/Public Health Expert, all of whom should be integrally involved throughout planning and implementation of research project.
Link: W81XWH-18-OCRP-OMCDA
 

Ovarian Cancer Academy Award - Early-Career Investigator
W81XWH-18-OCRP-OCA  

The Ovarian Cancer Academy is a virtual career development and research training platform consisting of Early-Career Investigators (ECIs) and their Designated Mentors from different institutions, and an Academy Dean and Assistant Dean.  This FY18 program announcement solicits additional Early-Career Investigators to join the existing Academy.  This award mechanism enables the Early-Career Investigator (PI on application) to pursue an ovarian cancer project that may be basic, translational, and/or clinical research (and, NEW for FY18, clinical trials), under the guidance of a Designated Mentor. The Designated Mentor is not required to be at the same institution as the ECI.
Amount & Project Period: $725,000 (Direct Costs) - 4 years
Eligibility: ECI must be w/in 3 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equiv. at time of full application submission (An eligibility letter is required);
Must not have concurrent Career Development-like award at time of this award;
Must have an institutional commitment of approx.. 50% protected time for ovarian cancer research and Academy activities incl. participation in monthly webinars;
Must commit no less than 25% effort to this award for first 2 years.
Designated mentor
Must demonstrate a commitment of at least 10% effort for mentoring and participating in off-site Academy activities;
Can only be a Designated Mentor to one OCA-ECI, so current Designated Mentors cannot be named in an FY18 application unless the period of performance of the current OCA-ECI award ends no later than July 2019.
See Program Announcement for additional details.
Link: PW81XWH-18-OCRP-OCA


NEW
July 26 (Pre-app.) All Faculty Ranks Federal Lung

Congressionally Directed Medical Research Programs
Lung Cancer Research Program (LCRP)
Concept Award
W81XWH-18-LCRP-CA

This award supports exploration of a highly innovative new concept or untested theory addressing an important problem relevant to lung cancer. It supports high-risk studies that having potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of lung cancer or develop an innovative and novel course of investigation.
Due Dates: Jul.  26 (Pre-application)
Applications Due:  Aug. 07 (OSR) Ι Aug. 09 (Sponsor)
Note: The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at http://orcid.org/.
Amount & Project Period: $100,000 - 1 year
Eligibility: Must be at or above postdoc (or equiv. level)
Contact: Office of Sponsored Research (x6804)
Links: W81XWH-18-LCRP-CA
General Application Instructions/Version 20180329


NEW
August 01 (LOI) All Ranks Non-federal Aging & Cancer

sens research foundation
Research Grants

Letters of Intent are accepted for new projects that fall within the research mission.  Letters must outline the specific SENS target related to the proposal, and how the project would advance research toward developing therapies to remove, repair, replace, or render that target harmless.
Due Dates: Aug. 01 (Letter of Intent)
Letters of Intent received by this date will be reviewed at the third quarter meeting of the Research Development Committee (RDC). Invited participants will have one year (or two submission deadlines) to submit a full proposal.
Additional Due Date:  February 01
Amount & Project Period: Funding levels not stated
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
sens fdn. contact: Lisa Fabiny, Operations Manager, Tel: (650) 336-1797
Link: Grant Submission Process
R21 NIH
NCI is a participating Institute
NEW
August 01 (LOI) All Ranks Federal mHealth/LMICs

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (Clinical Trial Optional)

The purpose is to encourage applications proposing to conduct research to develop or adapt innovative mobile health (mHealth) technology specifically suited for low and middle income countries (LMICs) and determine the health-related outcomes associated with implementation of the technology.  Applicants must propose partnerships between at least one U.S. institution and one LMIC institution, and proposed research plan should strengthen mHealth research capabilities at the LMIC institution. (See FOA Section II, Part 1 for NCI specific research interests).
Due Dates: Aug. 01 (Letter of Intent, not required or binding)
Applications Due:  Aug. 29 (OSR) Ι Aug. 31 (Sponsor)
Amount & Project Period: $250,000 (Direct Costs) -2 years
Eligibility: All Ranks - The main collaborators from proposed U.S. and LMIC institutions should serve as PDs/PIs or other key personnel. Individuals from non-U.S. high income country institutions are not eligible as PDs/PIs, but may participate as partners or collaborators in proposed programs.
Contact: Office of Sponsored Research (x6804)
FOA Link: PAR-18-242

NEW
August 11 (LOI) All Ranks Non-federal Mesothelioma

Meso Foundation
Research Grant Program  

 Eligible projects may relate to benchwork, translational, or clinical research not presently funded.  Encouraged projects include:
1. Strategies for early detection and prevention of mesothelioma;
2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment taking advantage of these targets;
3. Determination of clinical/molecular determinants for prognosis;
4. Research in peritoneal mesothelioma (1 grant for this research);
5. Therapeutic intervention, including but not limited to:
     a. Immune Response Targeted Therapy
     b. Novel chemotherapeutic compounds
     c. Novel radiation or surgical techniques
Due Dates: Aug. 11 (Letter of Intent)
Invited Applications Due:  Aug. 30 (OSR) Ι Sept. 01 (Sponsor)
Amount & Project Period: $100,000 - 2 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
Links: Meso Foundation Ι proposalCentral (Submission Site)
R01 NIH

NEW
August 20 (LOI) All Ranks Federal Rural Cancer Care

Improving the Reach and Quality of Cancer Care in Rural Populations (Clinical Trial Required)

This FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. The focus for observational studies (with pilot testing) is understanding and addressing the predictive and/or mediating role of social determinants of health, barriers to care, and treatment; and the focus for interventional research is on addressing quality of care related to cancer diagnosis, treatment and/or survivorship.
Due Dates: Aug. 20 (Letter of Intent, not required or binding)
Applications Due: Sept. 17 (OSR) Ι Sept. 19 (Sponsor)
Amount & Project Period: Applications proposing an observational study that includes pilot testing are limited to $400K/yr. (Direct Costs);
Applications proposing intervention projects are limited to $500K/yr. (Direct Costs)
Project Period:  5 years
Eligibility: All Ranks
Contact: Office of Sponsored Research (x6804)
RFA Link: RFA-CA-18-026

NEW
August 28 (Pre-app.) Junior Faculty Federal Career Development

Congressionally Directed Medical Research Programs
Peer Reviewed Cancer Research Program (PRCRP)
Career Development Award
W81XWH-18-PRCRP-CDA

  This award supports independent, early-career investigators to conduct impactful research with the guidance of an experienced cancer researcher.  This award supports impactful research projects with an emphasis on discovery. The early-career investigator is considered the PI, and application should focus on PI's research and career development. Preliminary data are not required.   Clinical trials are not allowed.
Due Dates: Aug.  28 (Pre-application)
Applications Due:  Sept. 24 (OSR) Ι Sept. 26 (Sponsor)
Amount & Project Period: $360,000 (Direct Costs) - 3 years
Eligibility: Must be independent, early-career researcher or physician-scientist w/in 10 years of completing terminal degree by application deadline (excludes time spent in residency or on family medical leave. Time spent as a postdoctoral fellow is not excluded).
Postdoctoral fellows are not eligible for this award.
Minimum of 30% protected time is required for the proposed research.
Contact: Office of Sponsored Research (x6804)
Links:  PRCRP Funding Opportunities
W81XWH-18-PRCRP-CDA
General Application Instructions/Version 20180329
Note: The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at http://orcid.org/.
Toolbox
Funding Opportunities

Funding Opportunity Calendar
OSR's Grant News
grants.gov
NCI Funding Opportunities
NIH Guide to Grants & Contracts

RaceTracks

 Federal Opportunities
Moffitt-Sponsored (Intramural) Opportunities
Opportunities Focused on Thoracic Oncology		 Grant Preparation

Proposal Submission Form
Grants.gov Instructions
PHS398 Instructions
NIH 2590 Instructions

News

 NIH Research Matters
The Cancer Letter
NIH News & Events
Federal Register
Science 360 News
 Other

PubMed
National Cancer Institute

Clinical Research

Who To Call in Clinical Research
Clinical Research FAQs
Data Safety Monitoring Plan
Liberty IRB
USF IRB
Questions?
MRISignals@moffitt.org